AB Corporate Bond ETF (EYEG) Price, Holdings, & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
6,602 shs
Average Volume
935,975 shs
Market Capitalization
$24.72 million
Assets Under Management
Dividend Yield
Net Expense Ratio
EYEG stock logo

About AB Corporate Bond ETF (NASDAQ:EYEG)

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

EYEG ETF News Headlines

See More Headlines
Receive EYEG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AB Corporate Bond ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Fund Name
AB Corporate Bond ETF
Tax Classification
Regulated Investment Company
Current Symbol
Inception Date
Fund Manager
Timothy Kurpis, Bernd Wuebben

Fund Focus

Asset Class
Fixed Income
Investment Grade
Development Level
Blended Development
Number of Holdings

Fund Statistics

Assets Under Management
Average Daily Volume

Administrator, Advisor and Custodian

State Street Bank and Trust Company
AllianceBernstein L.P.
State Street Bank and Trust Company
Foreside Fund Services, LLC
Transfer Agent
State Street Bank and Trust Company
Lead Market Maker
Jane Street


Creation Unit
Creation Fee
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

AB Corporate Bond ETF Expenses

TypeEYEGInvestment Grade ETFsFixed Income ETFsNASDAQ ETFsAll ETFs
Management Fee0.30%0.22%0.32%0.48%0.51%
Other Expenses0.00%0.12%0.27%0.34%0.58%
Total Expense0.30%0.25%0.40%0.58%0.70%
Fee Waiver0.00%-0.15%-0.24%-0.22%-0.57%
Net Expense0.30%0.22%0.35%0.54%0.58%

AB Corporate Bond ETF (EYEG)

Key Executives

  • Brian Matthew Strem
    President, Chief Executive Officer & Director
  • Sarah M. Romano
    Chief Financial & Accounting Officer
  • Lisa Brandano
    Vice President-Clinical Operations
  • Franz Obermayr
    Executive Vice President-Clinical Development
  • Brenda K. Mann
    Vice President-Research & Development

EYEG ETF - Frequently Asked Questions

How were AB Corporate Bond ETF's earnings last quarter?

AB Corporate Bond ETF (NASDAQ:EYEG) issued its quarterly earnings data on Thursday, August, 12th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.07.

How often does AB Corporate Bond ETF pay dividends? What is the dividend yield for AB Corporate Bond ETF?

AB Corporate Bond ETF announced a monthly dividend on Tuesday, April 30th. Shareholders of record on Thursday, May 2nd will be paid a dividend of $0.1484 per share on Tuesday, May 7th. This represents a $1.78 dividend on an annualized basis and a dividend yield of 5.04%. The ex-dividend date of this dividend is Wednesday, May 1st.
Read our dividend analysis for EYEG

What does EYEG invest in?

AB Corporate Bond ETF is a fixed income fund issued by AllianceBernstein. EYEG focuses on investment grade investments.

What is the management fee for AB Corporate Bond ETF?

AB Corporate Bond ETF's management fee is 0.30% and has no other recorded expenses or fee waivers. The net expense ratio for EYEG is 0.30%.

What other stocks do shareholders of AB Corporate Bond ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AB Corporate Bond ETF investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Novavax (NVAX), SCYNEXIS (SCYX), Trevena (TRVN), Exelixis (EXEL) and Gilead Sciences (GILD).

When did AB Corporate Bond ETF IPO?

AB Corporate Bond ETF (EYEG) raised $5 million in an IPO on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO.

This page (NASDAQ:EYEG) was last updated on 5/19/2024 by Staff

From Our Partners